PMS2 and gastric cancer: While MLH1 is most commonly lost in MSI-related gastric cancers, one study saw loss of MLH1/PMS2 in only 88% of MSI-H cases [19], and thus a single marker is expected to miss at least 10% of the MMR-deficient cases.